Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer by Tougeron, D et al.
Safety and outcome of definitive chemoradiotherapy in elderly
patients with oesophageal cancer
D Tougeron*,1, F Di Fiore
1, S Thureau
2, N Berbera
1, I Iwanicki-Caron
1, H Hamidou
2, B Paillot
1 and P Michel
1
1Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, Northwest Canceropole, 1 rue de Germont, Rouen Cedex 76031,
France;
2Department of Radiotherapy, CRLCC Becquerel, Northwest Canceropole, rue d’Amiens, Rouen 76000, France
Little is known about chemoradiotherapy (CRT) in elderly patients with a locally advanced oesophageal cancer (OC). The aim of our
study was to evaluate the tolerance and the outcome of elderly patients older than 70 years treated with CRT for a non-metastatic
OC. Chemoradiotherapy was based on radiotherapy combined with a cisplatin-based chemotherapy. Clinical complete response
(CCR) to CRT was evaluated on upper digestive endoscopy and computed tomography scan 6–8 weeks after CRT completion.
One hundred and nine consecutive patients were included. A CCR was observed in 63 patients (57.8%) and 2-year survival was
35.5%. Adverse events Xgrade 3 were observed in 26 (23.8%) patients. Chemotherapy dose reduction, chemotherapy delays more
than 1 week, and treatment discontinuation were observed in 33 (30.3%), 45 (41.3%), and 17 patients (15.6%), respectively.
Comorbidity index according to Charlson score was significantly associated with treatment tolerance. In multivariate analysis, a CCR
to CRT (Po0.01), a dose of radiotherapy X80% (P¼0.02), and a Charlson score p2( P¼0.046) were identified as independent
prognostic factors of overall survival. These results suggest that CRT could be considered as an effective treatment without major
toxicity in elderly patients with OC.
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Management of elderly patients with cancer is a therapeutic
challenge. It is well established that cancer occurs primarily in
elderly patients, with approximately two-thirds of cancer-related
death in the elderly over 60 years and 25% in patients older than 80
years. Oesophageal cancer (OC) is the eighth most common cancer
and the sixth cause of cancer mortality worldwide (Parkin, 2001).
In France, approximately 54% of OC occurs in patients older than
65 years, with 23% over 75 years (Remontet et al, 2003).
The most relevant treatment modalities in elderly patients with
OC remain a subject of debate. Although survival improvement has
been observed during the past decade, prognosis of OC has
remained significantly influenced by age (Bouvier et al, 2005;
Cranea et al, 2007). A recent population-based study including
patients with locoregional OC showed a difference in treatment
and survival according to age, comorbidity, race, and geographical
region (Steyerberg et al, 2007). It has also been reported that
elderly patients were less likely to undergo surgery and
chemotherapy, which was however partially explained by their
comorbidity (Steyerberg et al, 2007; Ruol et al, 2007a). Currently,
definitive chemoradiotherapy (CRT) based on the 5-fluorouracil–
cisplatin (5FU–CDDP) regimen has been considered in curative
intent in locally advanced or inoperable non-metastatic OC
(Kleinberg and Forastiere, 2007; National Cancer Institute
recommendations, 2008; Stahl and Oliveira, 2008).
Little is known about the efficacy of CRT in elderly patients with
a locally advanced OC. Indeed, data on tolerance and outcome in
these patients remain lacking. In the two recent randomised trials
that investigated the efficacy of CRT, the mean ages of included
patients were 59.1 and 57 years, respectively (Bedenne et al, 2007;
Stahl et al, 2005). Moreover, patients up to 70 years were not
eligible in the Stahl et al (2005) trial. More recently, in a limited
number of 25 patients older than 65 years, Anderson et al (2007)
reported that definitive chemoradiation using two cycles of 5FU
plus mitomycin-C associated with 50.4Gy radiation could be
considered as an active regimen with moderate toxicity.
The aim of our study was to evaluate the safety and the efficacy
of CRT in elderly patients older than 70 years treated for a non-
metastatic OC.
PATIENTS AND METHODS
Patient’s inclusion
All consecutive patients older than 70 years with a non-metastatic
OC treated with definitive CRT in Digestive Oncology Unit of
Rouen University Hospital between January 1994 and June 2007
were included. The ethical committee approved the procedure and,
due to the retrospective analysis with majority of died patients, any
patient contentment was necessary. Patient’s baseline character-
istics (dysphagia, WHO performance status, weight loss, albumine
rate, nutritional intervention namely enteral nutrition, and/or
Received 16 June 2008; revised 26 September 2008; accepted
30 September 2008; published online 28 October 2008
*Correspondence: Dr D Tougeron, Digestive Oncology Unit, Depart-
ment of Hepatogastroenterology, Rouen University Hospital, 1 rue de
Germont 76031 Rouen Cedex, France; E-mail: davidtougeron@hotmail.fr
British Journal of Cancer (2008) 99, 1586–1592
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sendoscopic dilation) were collected. Degree of dysphagia was
evaluated using the Atkinson (1977) score.
All patients had a histologically proven OC without visceral
metastasis at the time of diagnosis and were treated with definitive
CRT (Herskovic et al, 1992; Stahl et al, 2005; Bedenne et al, 2007).
Patients who had a cancer of the lower and the upper oesophagus
associated with an involvement of the coeliac or the sus-clavicular
lymph node areas (M1a stage), respectively, were also selected.
We used the Charlson score, which is widely used in
comorbidity index, for the analysis of patient’s comorbidities.
The Charlson score consists of 19 different disease comorbidity
categories (coronary artery disease, congestive heart failure,
chronic pulmonary disease, peptic ulcer disease, peripheral
vascular disease, liver disease, cerebrovascular disease, connective
tissue disease, diabetes, dementia, renal disease, prior tumour, and
AIDS), each allocated a weight of 1–6 based on the adjusted
relative risk of 1-year mortality and summed to provide a total
score.
Tumour staging
The tumour staging was based on the 1983 AJCC staging system
according to published recommendations (Coia et al, 2000).
Tumour evaluation was based on oesophagoscopy, barium
oesophagography, chest and abdominal computed tomography
(CT scan) (Bosset et al, 1997), and oesophageal ultrasonography
(Tio et al, 1990) when it was feasible. Tumour baseline
characteristics (TNM stage, location, length, diameter, and
histologic type) were collected. The tumour length was defined
by oesophagoscopy±barium oesophagography and tumour dia-
meter by endoscopic ultrasound and/or CT scan.
Treatment and CRT regimen
Patients received a CRT regimen based on the CDDP and 5FU
chemotherapy combination described by Herskovic et al (1992) or
on the CDDP/irinotecan chemotherapy combination described by
Michel et al (2006). The Herskovic CRT regimen was based on four
CDDP/5FU chemotherapy courses, which were delivered conco-
mitantly with 50–55Gy radiotherapy (weeks 1–5). Starting dose
regimens were 1000mgm
 2 at days 1–5 for 5FU and 75mgm
 2 at
day 1 for CDDP. The CRT regimen based on the CDDP/irinotecan
chemotherapy combination has been recently reported in a phase
II multicentric trial and consisted of eight chemotherapy courses
delivered concomitantly with 50–55Gy radiotherapy (courses five
to eight). Starting dose regimens were 60mgm
 2 for irinotecan
and 30mgm
 2 for CDDP at each cycle. Radiotherapy was delivered
5 days per week at 1.8 or 2Gyday
 1 in both CRT regimens. The
target volume of radiotherapy was the macroscopic tumour and
enlarged lymph nodes, if any, surrounded by 5-cm proximal and
distal margins and a 2-cm radial margin. The target was extended
to the inferior cervical area in cases of tumours located above the
carina. The specified dose was delivered at the intersection of the
central axis of the beams, according to international guidelines.
Twenty-five patients have an initial dose reduction due to their
age or comorbidities. Among these patients, the chemotherapy
start dose was generally 50 or 75% of complete dose.
At day 1 of each chemotherapy course, toxicities related to the
treatment were evaluated using the National Cancer Institute
Common Toxicity Criteria (NCI-CTC, version 2.0). We also noted
a delay of chemotherapy and CRT stop for toxicity. Percentage of
planned radiotherapy and chemotherapy dose was calculated.
Response to CRT and follow-up
Patients were considered to have a clinical complete response
(CCR) to CRT when no residual tumour was identified on upper
digestive endoscopy and when no metastatic disease occurrence
was observed on CT scan. This evaluation was performed 6–8
weeks after CRT completion. The follow-up was performed on a
clinical basis, with upper digestive endoscopy with biopsy and
chest and abdominal CT scans every 3 months. Local recurrence
was defined by positive biopsy at upper digestive endoscopy.
Salvage surgery in patients without CCR or with local recurrence
and absence of metastases were also collected. Follow-up data were
updated in December 2007. Among patients alive at 6 months,
median follow-up was 20.5 months (6–127 months).
Statistical analysis
Overall survival was calculated from the date of CRT initiation
until the date of death or the date of last follow-up. Survival curve
was established using Kaplan–Meier method. Disease-free survival
was estimated from the date of the first day of CRT initiation to the
time of documented failure (local recurrence or metastasis
occurrence) or the date of the last follow-up for those remaining
with CCR. Specific survival excluded patients who died of other
causes than cancer or treatment. Predictive factors of CCR to CRT
were determined by a univariate analysis and further evaluated in
multivariate logistic regression analysis. Predictive factors of
survival were studied by a univariate analysis and further
evaluated in multivariate Cox regression analysis to estimate the
hazard ratio (HR) with 95% confidence interval (CI). Nine pre-
defined baseline variables for the univariate analysis were sex, age,
WHO performance status o2, initial weight loss o10%, albumine
X30gl
 1, Charlson score p2, dose of cisplatin X80%, dose of
radiotherapy X80%, and CCR to CRT. Any variables reaching
P¼0.05 were introduced in multivariate analysis. We also
performed an analysis with stratification for age X75 years vs
o75 years and patients with or without comorditidies (Charlson
index p2 vs 42). All statistical analyses were performed with a
two-side significance value of 0.05. Statistical analysis was
performed using the Statview software (Statview for Windows,
SAS Institut Inc., version 5.0).
RESULTS
Patient and tumour characteristics
One hundred and nine patients over 70 years were analysed.
Clinical baseline characteristics are detailed in Table 1. Mean age
was 74.4±3.7, ranging from 70 to 88 years. There were 38 patients
(34.9%) aged more than 75 years. Majority of patients (79.8%) had
a good WHO performance index (0 or 1). Majority of patients had
a severe dysphagia X2 (70.6%) and 33.0% had an initial weight
lost X10%.
There were mainly T3 stage tumours (n¼76, 69.7%) and
squamous cell carcinoma (n¼77, 70.6%) (Table 2). Majority of
tumours were more than 5cm in length (55.0%), and 29.3% had a
diameter above 3cm.
Median Charlson score was 1 (range 0–6) (available in 88
patients). Twenty-seven patients (30.7%) had Charlson score X2
and 84% Charlson score X1. Majority of patients were autono-
mous at home (96.6%). Patients took, on an average, three
different medications per day. The prevalence of patients with
comorbidities was 84%. Thirteen patients (14.8%) had chronic
obstructive pulmonary disease, 12 patients (13.6%) had a prior or
concurrent malignancy, 11 patients (12.5%) had diabetes, and 10
patients (11.4%) had peripheral vascular disease.
Treatment regimen and tolerance
Eleven patients (10.1%) were started on enteral nutrition and 17
(15.6%) on endoscopic dilatation before starting the treatment
(Table 3). Ninety-eight patients (89.9%) had treatment with 5FU/
CDDP. Sixty-three (57.8%) patients received X80% of cisplatin
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splanned dose and 85 (78%) received X80% of radiotherapy
planned dose. Sixty-two patients (56.9%) experienced adverse
effects Xgrade 2, mainly vomiting and neutropaenia. Twenty-four
patients experienced grade 3 toxicity (22.0%), four an adverse
effect grade 4, with one toxic death (neutropaenia with peritonitis
caused by diverticular sigmoiditis). These adverse events con-
ducted to a treatment-related hospitalisation in 18 patients
(16.5%). Dose reduction for toxicity was performed in 33 patients
(30.3%), a chemotherapy delay of more than 1 week was required
in 45 patients (41.3%), and CRT discontinuation was necessary in
17 patients (15.6%). Finally, 42 patients (38.5%) completed the
planned CRT regimen.
Response to CRT, survival and outcome
Median overall survival was 15.2±2.8 months and disease-free
survival was 8.3±7.3 months (Figure 1) (Table 4). Two-year and
5-year survival rates were 35.5% (95% CI: 30.8–40.2) and 12.8%
(95% CI: 9.2–16.4), respectively. Distant metastasis occurred in 31
patients (28.4%) during follow-up. Cancer was the cause of death
in 73 patients (80.2%) among the patients who died (n¼91).
A CCR to CRT was observed in 63 patients (57.8%), and 26
(23.8%) of them had no recurrence at follow-up (median follow-up
was 20.5 months and eight patients were lost to follow-up). Median
overall survival in patients with CCR was 27.2±5.1 months as
compared with 6.0±2.5 months in non-responders (Po0.01)
(Figure 2). Among responders to CRT, 21 patients (33.3%) had a
local recurrence, with a median time of 13.4±2.2 months. Two
patients with local recurrence underwent surgery but the majority
of patients were treated by oesophageal stent (n¼9), chemother-
apy (n¼4), or the best supportive care (n¼6). In non-responder
patients to CRT, a salvage surgery was performed in five
patients. One patient died after surgery and three had local or
metastasis recurrence. Patients without CCR to CRT and surgical
contraindications were treated by oesophageal stent (n¼7),
chemotherapy (n¼3), or the best supportive care.
Prognostic factors of CCR to CRT and overall survival
Predictive factors of a CCR to CRT in univariate analysis were a
WHO performance status o2( P¼0.02), an initial weight loss
o10% (P¼0.01), a dose of cisplatin X80% (Po0.01), and a dose
of radiotherapy X80% (Po0.01) (Table 5). In multivariate
analysis, adjusted for sex and age, a dose of radiotherapy X80%
(HR¼12.1, 95% CI: 3.0–49.4; Po0.01) and a dose of cisplatin
X80% (HR¼3.4, 95% CI: 1.3–9.1; P¼0.01) were identified as
independent prognostic factors of CCR.
Predictive factors of overall survival in univariate analysis were
a CCR to CRT (Po0.01), a WHO performance status o2
(Po0.01), an initial weight loss o10% (P¼0.03), a dose of
cisplatin X80% (P¼0.03), a dose of radiotherapy X80%
(Po0.01), and a Charlson score p2( P¼0.02). T stage and age
o or 475 years were not predictive factors of overall survival in
univariate analysis (T stage, P¼0.85 and age o or 475 years,
Table 2 Tumour characteristics
n¼109
TNM stage (n, %)
T1N0 2 (1.8)
T1N1 0
T2N0 13 (11.9)
T2N1 5 (4.6)
T3N0 32 (29.3)
T3N1 44 (40.4)
T4N0 0
T4N1 2 (1.8)
Coeliac lymph nodes M1a 6 (5.5)
Sus-clavicular lymph nodes M1a 0
Unknown (M0) 5 (4.6)
Tumoral stage (n, %)
Stage I 2 (1.8)
Stage II 50 (45.9)
Stage III 46 (42.2)
Stage IV (M1a) 6 (5.5)
Unknown (M0) 5 (4.6)
Oesophagus tumoral location (n, %)
Lower one-third 52 (47.7)
Middle one-third 36 (33.3)
Upper one-third 21 (19.3)
Mean tumour length (cm, s.d.) 5.2±2.1
Mean tumour length X5cm (n, %) 60 (55.0)
Mean tumour diameter (cm, s.d.) 2.7±1.2
Mean tumour diameter X3cm(n, %) 32 (29.3)
Histological type (n, %)
Squamous cell carcinoma 77 (70.6)
Adenocarcinoma 28 (25.7)
Indifferentiated 4 (3.7)
Histological differentiation (n, %)
Well differentiated 26 (23.8)
Fairly differentiated 22 (20.2)
Poorly differentiated 12 (11.0)
Indifferentiated 5 (4.6)
Unknown 44 (40.4)
CT scan (n, %) 107 (98.2)
Echoendoscopy (n, %) 20 (18.3)
n¼number of patients; s.d.¼standard deviation.
Table 1 Patient characteristics
n¼109
Age (s.d., min–max) 74.4±3.7 (70–88)
Sex ratio (men/women) 90/19
WHO performance status (n, %)
0 24 (22.0)
1 63 (57.8)
2 22 (20.2)
WHO o2 87 (79.8)
Atkinson dysphagia score (n, %)
0 5 (4.6)
1 27 (24.8)
2 55 (50.4)
3 15 (13.8)
4 7 (6.4)
Dysphagia stage X2 77 (70.6)
Initial BMI (kgm
 2, s.d.) 24.9±6.8
Initial weight loss (%, s.d.) 7.7±6.6
Initial weight loss X10% (n, %) 36 (33.0)
Initial albumin (gl
 1, s.d.) 37.7±5.1
Creatinine clearance (mlmin
 1, s.d.) 73.2±22.3
Charlson score
a
Median (min–max) 1 (0–6)
Charlson score X2 27 (30.7%)
BMI¼body mass index; n¼number of patients; s.d.¼standard deviation.
aAvailable
for 88 patients.
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sP¼0.15). In multivariate analysis, adjusted for sex and age, a CCR
to CRT (27.2±5.1 months in responders vs 6.0±2.5 months in
non-responders; HR¼4.9, 95% CI: 2.5–9.5; Po0.01), a dose of
radiotherapy X80% (21.2±7.0 months if dose of radiotherapy
X80% vs 3.3±1.0 months if dose of radiotherapy o80%;
HR¼2.3, 95% CI: 1.3–4.2; P¼0.02), and a Charlson score p2
(13.9±3.6 months if Charlson score p2 vs 4.1±2.6 months if
Charlson score 42; HR¼2.1, 95% CI: 1.0–4.5; P¼0.046) were
identified as independent prognostic factors of overall survival.
Factors that influence treatment tolerance
Age X75 years was associated with worse creatinine clearance
(Po0.01) and more chemotherapy dose reduction at treatment
onset due to age (Po0.01), but this had no influence on total CRT
dose, adverse events, CCR to RCT, or overall survival. Patient with
a dose reduction at treatment onset was older but age did not
influence chemotherapy dose. This result was probably explained
by the fact that the patient with a dose reduction up front has a
secondary increase of chemotherapy dose if the tolerance was good
(nine patients).
Charlson score p2 vs 42 did not influence adverse events,
chemotherapy delay, CRT dose, or CCR to CRT, but only overall
survival. Nevertheless, patients with Charlson score X1 experi-
enced more adverse events grade X2 (76.5 vs 51.2%; P¼0.01) and
chemotherapy delay (66.7 vs 39.5%; P¼0.02).
DISCUSSION
This study suggested that definitive CRT in elderly patients with an
OC was an effective treatment without a major increase in adverse
events. Moreover, our results showed that CRT in elderly patients
produced a similar response rate and overall survival as usually
reported in younger patients treated with the same regimen. These
findings suggest that a treatment based on a CRT regimen may be
discussed in elderly patients. Improvements in general health care
Table 4 Patients’ outcome and survival
n¼109
Outcome in all patients n¼109
CCR to CRT (n, %) 63 (57.8)
Overall survival (months, s.d.) 15.2±2.8
Specific survival 19.5±1.9
Disease-free survival (months, s.d.) 8.3±7.3
Metastasis occurrence (n, %) 31 (28.4)
Mean time of metastasis occurrence (months, s.d.) 15.4±3.9
Outcome in patients with CCR n¼63
Local recurrence (n, %) 21 (33.3)
Mean time to local recurrence (months, s.d.) 13.4±2.2
Metastasis occurrence (n, %) 21 (33.3)
Mean time to metastasis occurrence (months, s.d.) 17.4±4.7
Median survival (months, s.d.) 27.2±5.1
Patient without recurrence 26 (23.8%)
Outcome in non-responders to CRT n¼46
Median survival (months, s.d.) 6.0±2.5
Causes of death n¼91
Cancer 73 (80.2%)
Treatment 2 (2.2%)
Others 14 (15.4%)
CCR¼clinical complete response; CRT¼chemoradiotherapy; n¼number of patients;
s.d.¼standard deviation.
Table 3 Treatment regimen and toxicity
n¼109
Treatment before CRT initiation (n, %)
Enteral nutrition by nasogastric tube 7 (6.4)
Enteral nutrition by stomy 4 (3.7)
Endoscopic dilation 17 (15.6)
Oesophageal stent 2 (1.8)
Chemotherapy regimen (n, %)
Irinotecan/CDDP 10 (9.2)
5-FU/CDDP 98 (89.9)
Other 1 (0.9)
Mean chemotherapy course
Irinotecan/CDDP regimen 6.2±2.6
5-FU/CDDP regimen 3.6±1.8
Mean radiotherapy dose (grays) 49.0±13.9
Treatment dose
% of cisplatin planned dose (%, s.d.) 69.0±27.4
% of cisplatin planned dose X80% 63 (57.8)
% of radiotherapy planned dose (%, s.d.) 89.8±22.9
% of radiotherapy planned dose X80% 85 (78.0)
Patients with adverse effects Xgrade 2 (n, %) 62 (56.9)
Patients with treatment delay more than 1 week (n, %) 45 (41.3)
Patients with treatment discontinuation (n, %) 17 (15.6)
Patients with chemotherapy dose reduction (n, %) 58 (53.2)
Due to adverse events 33 (30.3)
Due to age 25 (22.9)
Patients with treatment toxicity Xgrade 2 (n, %)
Neutropaenia 27 (24.8)
Vomiting 16 (14.7)
Mucitis 15 (13.8)
Infection 13 (11.9)
Diarrhoea 8 (7.3)
Renal insufficiency
a 6 (5.5)
CDDP/irinotecan regimen¼cisplatin and irinotecan chemotherapy combination;
CRT¼chemoradiotherapy; n¼number of patients; s.d.¼standard deviation; 5-FU/
CDDP regimen¼cisplatin and 5-fluorouracil chemotherapy combination.
aDiminu-
tion of creatinine clearance under 50mlmin
 1 after starting of chemotherapy.
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Figure 1 Overall survival. The median overall survival was 15.2±2.8
months.
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sand increased life expectancy have resulted in more elderly
patients with an OC. At 75 years of age, life expectancy was more
than 10 years (Arias, 2006). Therefore, if there are no major
comorbidities, elderly patients with OC should benefit from
curative treatment.
Definitive CRT is considered as a feasible non-surgical treatment
for patients with a locally advanced OC with approximately
50–65% CCR rate, 17–26 months of median overall survival, and
30–40% 2-year survival rate (Minsky et al, 1999; Ohtsu et al, 1999;
Coia et al, 2000; Seitz et al, 2000; Stahl et al, 2005; Michel et al,
2006; Di Fiore et al, 2006a; Bedenne et al, 2007). Interestingly, our
results in elderly patients were relatively close to those reported in
these series, with a CCR to CRT of 57.8% and a 2-year overall
survival rate of 35.5%. However, overall median survival in our
study (15.2 months) was slightly lower as compared with that
reported in previous randomised trials. These results were strictly
similar to those published by our group on series including
non-selected patients with an oesophageal carcinoma treated with
the same CRT regimens (Michel et al, 2006; Di fiore et al, 2006a,b;
Tougeron et al, 2008). Indeed, the mean age of patients ranged
from 39 to 88 years in these series and we found that the complete
response to CRT was 50–80% and the overall survival was 16–20
months as in this study in elderly patients. Although age and
comorbidity were associated with higher difficulties encountered
during treatment, no significant association was found between
these factors and survival in our study. Moreover, the difference in
median overall survival could be partially explained by a selection
bias in these prospective trials, whereas our study possibly
reflected the outcome of non-selected patients. In a recent study,
predictive factors of prognosis in locally advanced OC from the
randomised FFCD 9102 trial in the multivariate analysis were age
more than 65 years, inability to ingest solid food, and the presence
of more than three neoplastic coeliac lymph nodes on endoscopic
ultrasonography (Burtin et al, 2008).
Anderson et al (2007) reported significant results from a single
institution experience of chemoradiation in 25 elderly patients
older than 65 years with OC. On the basis of a median follow-up of
32 months, the CCR rate was 68% and the 2-year survival rate was
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Patients with CCR to CRT
Patients without CCR to CRT
Figure 2 Overall survival in responders and non-responders to CRT.
The median overall survival was 27.2±5.1 months in responder patients as
compared with 6.0±2.5 months in non-responder patients (Po0.01).
CCR¼clinical complete response; CRT¼chemoradiotherapy.
Table 5 Univariate and multivariate analysis of CCR to CRT and overall survival
Univariate analysis Multivariate analysis
Response rate or
median survival P-value HR (95% CI) P-value
Predictive factors of CCR to CRT
a
WHO performance status o2 P¼0.02 NS
Initial weight loss o10% P¼0.01 NS
Albumine X30gl
 1 P¼0.61
Dose of cisplatin X80% Po0.01 12.1 (3.0–49.4) Po0.01
Yes 76.1%
No 44.4%
Dose of radiotherapy X80% Po0.01 3.4 (1.3–9.1) Po0.01
Yes 70.6%
No 12.5%
Charlson score p2 P¼0.76
Predictive factors of overall survival
b
CCR to CRT Po0.01 4.9 (2.5–9.5) Po0.01
Yes 27.2±5.1
No 6.0±2.5
WHO performance status o2 Po0.01 NS
Initial weight loss o10% P¼0.03 NS
Albumine X30gl
 1 P¼0.43
Dose of cisplatin chemotherapy X80% P¼0.03 NS
Dose of radiotherapy X80% Po0.01 2.3 (1.3-4.2) P¼0.02
Yes 21.2±7.0
No 3.3±1.0
Charlson score p2P ¼0.02 2.1 (1.0–4.5) P¼0.046
Yes 13.9±3.6
No 4.1±2.6
CCR¼clinical complete response; CI¼confidence interval; CRT¼chemoradiotherapy; HR¼hazard ratio; NS, nonsignificant.
aMultivariate logistic regression analysis adjusted
on sex and age.
bMultivariate Cox regression analysis adjusted on sex and age.
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s64% (95% CI: 45–83) in this study. The overall survival was very
good probably because there was a careful selection of patients
using Charlson score and data were only available on 25 patients
with a very significant CI for survival rate. Different findings were
found in the Takeuchi et al (2007) study in which results of CRT
based on 5FU/CCDP and 60Gy of radiation were compared
between 33 elderly patients vs 145 non-elderly. In fact, a significant
worse survival and higher CRT discontinuation and toxicity were
reported in elderly. These contradictory results strongly support
that more data on larger population, as in our study, are required
to accurately estimate the safety and efficacy of the CRT approach
in an elderly population. Local recurrence and metastasis
occurrence in our study were in accordance with randomised
trials (Minsky et al, 1999; Seitz et al, 2000; Bedenne et al, 2007).
Salvage oesophagectomy has been reported in a small group of
elderly patients who did not respond to CRT. Five patients
underwent surgery in our series and only one in the study of
Anderson et al (2007). Death due to post-operative complications
occurred in one patient in our study and also in one patient in the
Anderson et al (2007) study. Although a significant improvement
has been obtained in post-operative resuscitation, oesophagectomy
for OC remains associated with significant morbidity and mortality
rates. In this context, surgical approach in patients older than 70
years with OC is still debated because of potentially higher post-
operative complication rates (Poon et al, 1998; Law et al, 2004;
Moskovitz et al, 2006). On the basis of a population of 421 patients
with intrathoracic squamous cell carcinoma treated with surgical
resection, Law et al (2004) found that age was significantly
associated with pulmonary complications and hospital mortality.
In a single institution study on 751 patients including 31 patients
older than 80 years, Moskovitz et al (2006) reported that post-
operative death and hospital length of stay were significantly worse
in elderly patients, independently of comorbidity. In contrast, Ruol
et al (2007b,c) recently showed similar short- and long-term post-
operative outcomes in elderly patients as compared with younger
patients. This difference could be due to difference in surgical and
resuscitation experience between centres. Median survival after
oesophagectomy remains poor in elderly patients, ranging from 6
to 27 months, with major post-operative mortality ranging from
4.7 to 7.2% (Thomas et al, 1996; Poon et al, 1998; Sabel et al, 2002;
Internullo et al, 2008).
In our study, the planned treatment was achieved in only 38.5%
of patients, and 53.2% of them required dose adjustment.
However, grade 4 toxicity was observed only in three patients
(2.7%), with two treatment-related deaths (1.8%). In the Anderson
et al (2007) study, 88% of patients completed the planned CRT,
grade 4 toxicity occurred in 16%, and no treatment-related deaths
were observed. Moreover, severe adverse events (grade 3 or 4) were
observed in 23.8% of patients in this study and 31% of patients
randomised in the definitive CRT arm of FFCD 9102 study.
Chemoradiotherapy tolerance in ‘selected’ elderly patients with an
OC was acceptable as compared with younger patients, but a dose
reduction was frequently necessary due to adverse events. Age
X75 years had no influence on adverse events. These results
underlined that age criteria alone is not sufficient for guidance of
therapy and that better characterisation of patients with Charslon
score, for example, may be helpful for decision making.
5-Fluorouracil tolerance was the same in the elderly and younger
patients (Popescu et al, 1999). Moreover, a recent study on patients
with an advanced oesophagogastric adenocarcinoma suggested
that cisplatin-based chemotherapy toxicities did not increase with
age (Trumper et al, 2006). In patients with other cancers (rectum,
lung, or head and neck cancers) treated with concomitant CRT, the
same results were observed. In these elderly patients treated with
CRT for other tumours, no major toxicity was observed with
similar survival rates than in younger patients (Airoldi et al, 2004;
Pasetto et al, 2006; Semrau et al, 2007).
The main reported predictive factors of response to CRT and
overall survival were WHO performance status, nutritional status,
treatment dose, and TNM stage (Coia et al, 2000; Polee et al, 2003;
Rohatgi et al, 2005; Di Fiore et al, 2006a). No major difference was
found, in our multivariate analysis, in predictive factors of CCR to
CRT and survival in elderly patients. Although age and Charlson
score were associated with nutritional impairment and a greater
chemotherapy dose reduction, our analysis also underlined that
the success rate of CRT in OC was not dependant on age.
In conclusion, our results showed that definitive CRT could be
considered as an effective treatment with no significant toxicity in
elderly patients with OC.
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